logo

Actinium Pharmaceuticals Inc (ATNM)



Trade ATNM now with
  Date
  Headline
5/1/2018 7:31:52 AM Actinium Adds Jeffrey Chell To Board
4/18/2018 7:31:49 AM Actinium Strengthens Targeted Myeloablation Focused Clinical Development Team
4/11/2018 7:31:34 AM Actinium Pharma To Showcase Capabilities Of Its AWE Technology Platform In Developing Biobetters
3/28/2018 8:02:18 AM Actinium Announces Collaborative Research Partnership With Astellas Leveraging Actinium’s AWE Platform Tech
3/14/2018 7:31:34 AM Actinium Pharma Appoints Jehan Rowlands As VP, Head Of Regulatory Affairs
3/13/2018 7:33:01 AM Actinium Reports FDA Clearance Of IND For Phase 1 Trial Of Actimab-A In Combination With CLAG-M
2/27/2018 7:31:28 AM Actinium Activates Sixteen Clinical Trial Sites In Pivotal Phase 3 SIERRA Trial
2/26/2018 10:05:18 AM Actinium Reiterates Expiration Date Of March 2, 2018 At 5:00 PM ET And Amendment To Pricing Terms Of Rights Offering
2/22/2018 7:33:07 AM Actinium Announces Commencement Of Rights Offering Subscription Period
2/20/2018 7:32:58 AM Actinium Announces Product Showcase And Other Visibility Extending Activities At The BMT Tandem Meetings
2/8/2018 8:04:38 AM Actinium Names Anil Kapur Chief Commercial Officer
2/6/2018 7:32:53 AM Actinium Pharma Unveils Trial To Study Actimab-A With CLAG-M For Relapsed Or Refractory AML Patients
2/1/2018 7:35:53 AM Actinium Pharma Announces Acceptance Of Abstract Showcases The Potential Of Actinium’s AWE Technology Platform At AACR
1/8/2018 7:33:40 AM Actinium Pharmaceuticals Names Dale Ludwig Chief Scientific Officer
12/27/2017 9:01:14 AM Actinium Update On Phase 3 Trial Of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
12/12/2017 7:35:14 AM Actinium Highlights Promising Data From AWE Program At ASH
12/11/2017 6:32:43 AM Actinium Reports Positive Preliminary Results From Phase 2 Trial For Actimab
12/6/2017 11:43:19 AM B. Riley FBR Starts Actinium Pharmaceuticals Inc (ATNM) At Buy With $2.75 Price Target